Сторінка 1 від 77 результати
This application is a 371 of PCT/GB93/00445, filed on Mar. 4, 1993.
FIELD OF THE INVENTION
This invention is directed to sulfur-containing aromatic compounds which are useful in inhibiting cyclic AMP phosphodiesterase or tumor necrosis factor. The invention is also directed to the preparation of
TECHNICAL FIELD
The present disclosure relates to compounds that treat cancer and/or treat or prevent cancer metastasis. In particular, the subject technology is directed to halogenated phenylethynyl-substituted benzenes bearing nitrogen-containing heterocycles attached to the benzene and directed
TECHNICAL FIELD
The present disclosure is generally related to N-substituted tetrahydroisoquinoline benzamide and benzene sulfonamide compounds and their use in modulating the proliferation of transformed (cancer) cells.
BACKGROUND
Cancer is a disease in which cells in the body grow out of control.
BACKGROUND OF THE INVENTION
The invention relates to a new class of compounds, a pharmaceutical composition thereof, a method of preparing a medicament for the treatment of a cancer, and a method of treating cancers. It finds particular application in conjunction with the treatment of breast cancer,
FIELD OF THE INVENTION
The present invention relates to uses of a hydroxy-substituted benzophenone compound having a symmetrical or asymmetric structure in the preparation of antiviral and antitumor drugs, and more particularly relates to uses of one or more hydroxy-substituted benzophenone
TECHNICAL FIELD
This invention relates to compounds and methods for inducing or promoting apoptosis and for arresting uncontrolled neoplastic cell proliferation, methods that are specifically useful in the arresting and treatment of neoplasias, including precancerous and cancerous
This application is the national phase of international application PCT /GB98/00910 filed Mar. 25, 1998.
This invention relates to hydroxamic acid compounds and in particular to such compounds with a heterocyclicalkoxy substituent. This invention further relates to processes for preparing such
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national stage filing under section 371 of International Application No. PCT/EP2016/053172, filed on Feb. 15, 2016, and published on Aug. 25, 2016 as WO 2016/131776, which claims priority to Great Britain Application No. 1502567.9, filed
BACKGROUND OF THE INVENTION
There is an ongoing need for new agents as inhibitors of EZH2 activity, which can be used for treating EZH2-mediated disorder (e.g., cancer).
SUMMARY OF THE INVENTION
In one aspect, the present invention features a substituted benzene compound selected from
##STR00001##
INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING
The contents of the text file named "EPIZ-014001US-ST25.txt", which was created on Feb. 5, 2015 and is 1.3 KB in size, are hereby incorporated by reference in their entireties.
BACKGROUND OF THE INVENTION
There is an ongoing need for new agents as
INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING
The contents of the text file named "EPIZ-025N01US-ST25.txt", which was created on Jan. 7, 2015 and is 2 KB in size, are hereby incorporated by reference in their entireties.
BACKGROUND OF THE INVENTION
There is an ongoing need for new agents as
INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING
The contents of the text file named "EPIZ-014001US-ST25.txt", which was created on Feb. 5, 2015 and is 1.3 KB in size, are hereby incorporated by reference in their entireties.
BACKGROUND OF THE INVENTION
There is an ongoing need for new agents as
INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING
The contents of the text file named "EPIZ-029N01US-ST25.txt", which was created on Apr. 14, 2015 and is 5 KB in size, are hereby incorporated by reference in their entireties.
PARTIES TO JOINT RESEARCH AGREEMENT
This invention was developed subject to a
INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING
The contents of the text file named "EPIZ-014001US-ST25.txt", which was created on Feb. 5, 2015 and is 1.3 KB in size, are hereby incorporated by reference in their entireties.
BACKGROUND OF THE INVENTION
There is an ongoing need for new agents as
FIELD OF THE INVENTION
This present invention is related to the use of azolidinone-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral